FDA approves HYRNUO® (sevabertinib) for adults with HER2 activating mutations in non-small cell lung cancer post-systemic therapy.
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
December 5, 2025 at 10:10 PM
FDA approves HYRNUO® (sevabertinib) for adults with HER2 activating mutations in non-small cell lung cancer post-systemic therapy.
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
🌍 Climate change impacts kidney health.
This #WorldKidneyDay, protect your kidneys and the planet.
Learn more: www.worldkidneyday.org/2026-campaign/
Take the kidney quiz: kidneyquiz.theisn.org
Find the clinical evidence on treatments @DRUGDOCS®.
#OurKidneysOurPlanet #KidneyHealthForAll #DrugDocs
This #WorldKidneyDay, protect your kidneys and the planet.
Learn more: www.worldkidneyday.org/2026-campaign/
Take the kidney quiz: kidneyquiz.theisn.org
Find the clinical evidence on treatments @DRUGDOCS®.
#OurKidneysOurPlanet #KidneyHealthForAll #DrugDocs
2026 campaign - World Kidney Day 2026
World Kidney Day – 12 March 2026 Kidney Health For All – Caring for People, Protecting the Planet Are Your Kidneys OK? Take this quiz! Kidney Health for All Caring for People, Protecting the Planet Ch...
www.worldkidneyday.org
March 12, 2026 at 3:44 PM
🌍 Climate change impacts kidney health.
This #WorldKidneyDay, protect your kidneys and the planet.
Learn more: www.worldkidneyday.org/2026-campaign/
Take the kidney quiz: kidneyquiz.theisn.org
Find the clinical evidence on treatments @DRUGDOCS®.
#OurKidneysOurPlanet #KidneyHealthForAll #DrugDocs
This #WorldKidneyDay, protect your kidneys and the planet.
Learn more: www.worldkidneyday.org/2026-campaign/
Take the kidney quiz: kidneyquiz.theisn.org
Find the clinical evidence on treatments @DRUGDOCS®.
#OurKidneysOurPlanet #KidneyHealthForAll #DrugDocs
📊 July’s Top 3 on DRUGDOCS®
Epidiolex® returns to #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Aqneursa® – Niemann–Pick disease type C
3️⃣ Dayvigo® – Adult insomnia
🔗 Explore the evidence: drugdocs.com
Epidiolex® returns to #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Aqneursa® – Niemann–Pick disease type C
3️⃣ Dayvigo® – Adult insomnia
🔗 Explore the evidence: drugdocs.com
August 11, 2026 at 2:20 PM
📊 July’s Top 3 on DRUGDOCS®
Epidiolex® returns to #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Aqneursa® – Niemann–Pick disease type C
3️⃣ Dayvigo® – Adult insomnia
🔗 Explore the evidence: drugdocs.com
Epidiolex® returns to #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Aqneursa® – Niemann–Pick disease type C
3️⃣ Dayvigo® – Adult insomnia
🔗 Explore the evidence: drugdocs.com
FDA approves #Blenrep (belantamab mafodotin-blmf) combo for relapsed/refractory multiple myeloma. DREAMM-7 showed improved survival vs comparator. REMS required due to ocular toxicity.
🔗 Read more: www.fda.gov/drugs/resour...
📄 Find the clinical evidence at DRUGDOCS®: drugdocs.com/drug/Blenrep
🔗 Read more: www.fda.gov/drugs/resour...
📄 Find the clinical evidence at DRUGDOCS®: drugdocs.com/drug/Blenrep
November 14, 2025 at 8:13 PM
FDA approves #Blenrep (belantamab mafodotin-blmf) combo for relapsed/refractory multiple myeloma. DREAMM-7 showed improved survival vs comparator. REMS required due to ocular toxicity.
🔗 Read more: www.fda.gov/drugs/resour...
📄 Find the clinical evidence at DRUGDOCS®: drugdocs.com/drug/Blenrep
🔗 Read more: www.fda.gov/drugs/resour...
📄 Find the clinical evidence at DRUGDOCS®: drugdocs.com/drug/Blenrep
Brinsupri achieves FDA approval as the 1st treatment for non-cystic fibrosis bronchiectasis. It also launches the novel DPP1 inhibitor class, blocking enzymes that fuel harmful lung inflammation. Big news for chronic lung disease.
💊 Find the clinical evidence @DrugDocs: drugdocs.com/drug/Brinsupri
💊 Find the clinical evidence @DrugDocs: drugdocs.com/drug/Brinsupri
August 21, 2025 at 10:48 PM
Brinsupri achieves FDA approval as the 1st treatment for non-cystic fibrosis bronchiectasis. It also launches the novel DPP1 inhibitor class, blocking enzymes that fuel harmful lung inflammation. Big news for chronic lung disease.
💊 Find the clinical evidence @DrugDocs: drugdocs.com/drug/Brinsupri
💊 Find the clinical evidence @DrugDocs: drugdocs.com/drug/Brinsupri
Genentech & Novartis have teamed up with FARE, a nonprofit advocating for food allergy awareness.
Launched 1 yr ago, #Xolair, the only drug indicated for people w/ food allergies, is already used by 40K+ patients offering new hope.
💊 Find the clinical evidence @ DRUGDOCS® drugdocs.com/drug/Xolair
Launched 1 yr ago, #Xolair, the only drug indicated for people w/ food allergies, is already used by 40K+ patients offering new hope.
💊 Find the clinical evidence @ DRUGDOCS® drugdocs.com/drug/Xolair
March 5, 2025 at 2:35 PM
Genentech & Novartis have teamed up with FARE, a nonprofit advocating for food allergy awareness.
Launched 1 yr ago, #Xolair, the only drug indicated for people w/ food allergies, is already used by 40K+ patients offering new hope.
💊 Find the clinical evidence @ DRUGDOCS® drugdocs.com/drug/Xolair
Launched 1 yr ago, #Xolair, the only drug indicated for people w/ food allergies, is already used by 40K+ patients offering new hope.
💊 Find the clinical evidence @ DRUGDOCS® drugdocs.com/drug/Xolair
Multiple potential blockbuster drug launches are expected in 2026. Top drugs include:
• CagriSema & orforglipron (obesity/Type 2 diabetes)
• anito-cel (multiple myeloma)
• brepocitinib (dermatomyositis)
• gedatolisib (breast cancer)
Follow DRUGDOCS® for the clinical evidence as they are approved.
• CagriSema & orforglipron (obesity/Type 2 diabetes)
• anito-cel (multiple myeloma)
• brepocitinib (dermatomyositis)
• gedatolisib (breast cancer)
Follow DRUGDOCS® for the clinical evidence as they are approved.
Top 10 most anticipated drug launches of 2026
Like last year, 2026 appears poised to herald the arrival of multiple mega-blockbusters—albeit on an even grander scale than 2025’s plenty-respectable slate of major rollouts.According to Evaluate’s a...
www.fiercepharma.com
February 19, 2026 at 2:58 PM
Multiple potential blockbuster drug launches are expected in 2026. Top drugs include:
• CagriSema & orforglipron (obesity/Type 2 diabetes)
• anito-cel (multiple myeloma)
• brepocitinib (dermatomyositis)
• gedatolisib (breast cancer)
Follow DRUGDOCS® for the clinical evidence as they are approved.
• CagriSema & orforglipron (obesity/Type 2 diabetes)
• anito-cel (multiple myeloma)
• brepocitinib (dermatomyositis)
• gedatolisib (breast cancer)
Follow DRUGDOCS® for the clinical evidence as they are approved.
Biotech is navigating market uncertainty, but H2 2025 could bring much-needed momentum. Major trial results are expected, and obesity, Alzheimer’s, MS, and eczema are all in focus.
📖 Read about the trials to watch below.
As new drugs are approved, visit DRUGDOCS® for the current best evidence.
📖 Read about the trials to watch below.
As new drugs are approved, visit DRUGDOCS® for the current best evidence.
10 clinical trials to watch the rest of 2025
Expected readouts in obesity, lung cancer and AATD headline a series of study results that could give the biotechnology sector a boost.
www.biopharmadive.com
July 30, 2025 at 2:09 PM
Biotech is navigating market uncertainty, but H2 2025 could bring much-needed momentum. Major trial results are expected, and obesity, Alzheimer’s, MS, and eczema are all in focus.
📖 Read about the trials to watch below.
As new drugs are approved, visit DRUGDOCS® for the current best evidence.
📖 Read about the trials to watch below.
As new drugs are approved, visit DRUGDOCS® for the current best evidence.
📢 Merck’s Capvaxive, built for seniors, is proving effective in kids too.
✔️ Strong immune response in 21 serotypes
✔️ Superior to Pneumovax in unique serotypes
✔️ Favorable safety profile
🧪 Follow @DRUGDOCS for the clinical data when it’s approved in children and adolescents.
✔️ Strong immune response in 21 serotypes
✔️ Superior to Pneumovax in unique serotypes
✔️ Favorable safety profile
🧪 Follow @DRUGDOCS for the clinical data when it’s approved in children and adolescents.
Despite being designed for seniors, Merck's pneumococcal shot shows potential in children
Approved 15 months ago as a pneumococcal disease vaccine for adults—and billed as the first shot designed for seniors—Merck’s Capvaxive now has data
www.fiercepharma.com
September 23, 2025 at 8:09 PM
📢 Merck’s Capvaxive, built for seniors, is proving effective in kids too.
✔️ Strong immune response in 21 serotypes
✔️ Superior to Pneumovax in unique serotypes
✔️ Favorable safety profile
🧪 Follow @DRUGDOCS for the clinical data when it’s approved in children and adolescents.
✔️ Strong immune response in 21 serotypes
✔️ Superior to Pneumovax in unique serotypes
✔️ Favorable safety profile
🧪 Follow @DRUGDOCS for the clinical data when it’s approved in children and adolescents.
Scientists are rethinking migraine from a whole-brain perspective, uncovering why it happens & how to stop it.
New drugs like gepants are transforming lives, but there’s more to do. www.nature.com/articles/d41...
Find the evidence for FDA approved gepants @ DRUGDOCS®: drugdocs.com/search/gepant
New drugs like gepants are transforming lives, but there’s more to do. www.nature.com/articles/d41...
Find the evidence for FDA approved gepants @ DRUGDOCS®: drugdocs.com/search/gepant
Migraine is more than a headache — a radical rethink offers hope to one billion people
Drugs that can prevent or relieve migraine attacks are only effective for some people. Research is starting to untangle the reasons why.
www.nature.com
February 26, 2025 at 2:28 PM
Scientists are rethinking migraine from a whole-brain perspective, uncovering why it happens & how to stop it.
New drugs like gepants are transforming lives, but there’s more to do. www.nature.com/articles/d41...
Find the evidence for FDA approved gepants @ DRUGDOCS®: drugdocs.com/search/gepant
New drugs like gepants are transforming lives, but there’s more to do. www.nature.com/articles/d41...
Find the evidence for FDA approved gepants @ DRUGDOCS®: drugdocs.com/search/gepant
🚀💊 PharmaTimes has recently highlighted 15 years of pharma breakthroughs: mRNA, CAR-T, GLP-1s—shifting care toward precision, prevention, and even cures.
Access to clinical evidence is key to making sense of it all.
📖 Read the article below.
💊 Explore more DRUGDOCS®: drugdocs.com
Access to clinical evidence is key to making sense of it all.
📖 Read the article below.
💊 Explore more DRUGDOCS®: drugdocs.com
22-23 PHARMA - Fast and the curious
This month: the NHS as a dystopian game of Tetris, the GLP-1 explosion and its impact on future meds, plus deep dives into AI in pharma, reproductive health, and Trump’s healthcare influence. Also, co...
magazine.pharmatimes.com
May 1, 2026 at 2:56 PM
🚀💊 PharmaTimes has recently highlighted 15 years of pharma breakthroughs: mRNA, CAR-T, GLP-1s—shifting care toward precision, prevention, and even cures.
Access to clinical evidence is key to making sense of it all.
📖 Read the article below.
💊 Explore more DRUGDOCS®: drugdocs.com
Access to clinical evidence is key to making sense of it all.
📖 Read the article below.
💊 Explore more DRUGDOCS®: drugdocs.com
📊 August’s Top 3 on DRUGDOCS®
Epidiolex® holds onto #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Opdivo® – Cancer immunotherapy
3️⃣ Zolymbus® – Glaucoma and ocular hypertension
🔗 Explore the evidence @ drugdocs.com
Epidiolex® holds onto #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Opdivo® – Cancer immunotherapy
3️⃣ Zolymbus® – Glaucoma and ocular hypertension
🔗 Explore the evidence @ drugdocs.com
September 9, 2026 at 3:59 PM
📊 August’s Top 3 on DRUGDOCS®
Epidiolex® holds onto #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Opdivo® – Cancer immunotherapy
3️⃣ Zolymbus® – Glaucoma and ocular hypertension
🔗 Explore the evidence @ drugdocs.com
Epidiolex® holds onto #1, joined by two new entries:
1️⃣ Epidiolex® – Rare seizure disorders
2️⃣ Opdivo® – Cancer immunotherapy
3️⃣ Zolymbus® – Glaucoma and ocular hypertension
🔗 Explore the evidence @ drugdocs.com
Friday reminder that laughter can be the best medicine.
In the below article, a cardiologist reflects on how humor can ease anxiety, build trust, and make care feel more human.
DRUGDOCS will stick to the clinical evidence, but we support a good laugh along the way.
voices.nejm.org/doi/full/10....
In the below article, a cardiologist reflects on how humor can ease anxiety, build trust, and make care feel more human.
DRUGDOCS will stick to the clinical evidence, but we support a good laugh along the way.
voices.nejm.org/doi/full/10....
August 28, 2026 at 2:51 PM
Friday reminder that laughter can be the best medicine.
In the below article, a cardiologist reflects on how humor can ease anxiety, build trust, and make care feel more human.
DRUGDOCS will stick to the clinical evidence, but we support a good laugh along the way.
voices.nejm.org/doi/full/10....
In the below article, a cardiologist reflects on how humor can ease anxiety, build trust, and make care feel more human.
DRUGDOCS will stick to the clinical evidence, but we support a good laugh along the way.
voices.nejm.org/doi/full/10....
🔬 August 18 is #WorldBreastCancerResearchDay.
Today we recognize the research driving progress in breast cancer—from new targets to new treatments.
💊 Explore clinical evidence on breast cancer therapies at DRUGDOCS: drugdocs.com
📌 worldbreastcancerresearchday.org
Today we recognize the research driving progress in breast cancer—from new targets to new treatments.
💊 Explore clinical evidence on breast cancer therapies at DRUGDOCS: drugdocs.com
📌 worldbreastcancerresearchday.org
August 18, 2026 at 2:25 PM
🔬 August 18 is #WorldBreastCancerResearchDay.
Today we recognize the research driving progress in breast cancer—from new targets to new treatments.
💊 Explore clinical evidence on breast cancer therapies at DRUGDOCS: drugdocs.com
📌 worldbreastcancerresearchday.org
Today we recognize the research driving progress in breast cancer—from new targets to new treatments.
💊 Explore clinical evidence on breast cancer therapies at DRUGDOCS: drugdocs.com
📌 worldbreastcancerresearchday.org
Today is #WorldHepatitisDay.
Proven tools can prevent, diagnose and treat viral hepatitis, but barriers to awareness, testing, and care remain.
💊 Explore evidence on hepatitis treatments at DRUGDOCS: drugdocs.com
📌 Learn more: www.worldhepatitisday.org
Proven tools can prevent, diagnose and treat viral hepatitis, but barriers to awareness, testing, and care remain.
💊 Explore evidence on hepatitis treatments at DRUGDOCS: drugdocs.com
📌 Learn more: www.worldhepatitisday.org
July 28, 2026 at 7:47 PM
Today is #WorldHepatitisDay.
Proven tools can prevent, diagnose and treat viral hepatitis, but barriers to awareness, testing, and care remain.
💊 Explore evidence on hepatitis treatments at DRUGDOCS: drugdocs.com
📌 Learn more: www.worldhepatitisday.org
Proven tools can prevent, diagnose and treat viral hepatitis, but barriers to awareness, testing, and care remain.
💊 Explore evidence on hepatitis treatments at DRUGDOCS: drugdocs.com
📌 Learn more: www.worldhepatitisday.org
📊 June’s Top 3 on DRUGDOCS®
Zolymbus® and Epidiolex® remain the two most-searched drugs for a third month, but have switched positions:
1️⃣ Zolymbus® – Elevated eye pressure
2️⃣ Epidiolex® – Rare seizure disorders
3️⃣ WAKIX® – Narcolepsy
🔗 drugdocs.com
Zolymbus® and Epidiolex® remain the two most-searched drugs for a third month, but have switched positions:
1️⃣ Zolymbus® – Elevated eye pressure
2️⃣ Epidiolex® – Rare seizure disorders
3️⃣ WAKIX® – Narcolepsy
🔗 drugdocs.com
July 24, 2026 at 1:47 PM
📊 June’s Top 3 on DRUGDOCS®
Zolymbus® and Epidiolex® remain the two most-searched drugs for a third month, but have switched positions:
1️⃣ Zolymbus® – Elevated eye pressure
2️⃣ Epidiolex® – Rare seizure disorders
3️⃣ WAKIX® – Narcolepsy
🔗 drugdocs.com
Zolymbus® and Epidiolex® remain the two most-searched drugs for a third month, but have switched positions:
1️⃣ Zolymbus® – Elevated eye pressure
2️⃣ Epidiolex® – Rare seizure disorders
3️⃣ WAKIX® – Narcolepsy
🔗 drugdocs.com
🎆 Happy Fourth of July!
Wishing our friends, colleagues, partners, and followers across the United States a wonderful Independence Day filled with celebration, good time with family and friends, and summer traditions.
Have a safe, happy, and memorable holiday!
#FourthOfJuly #July4 #DrugDocs
Wishing our friends, colleagues, partners, and followers across the United States a wonderful Independence Day filled with celebration, good time with family and friends, and summer traditions.
Have a safe, happy, and memorable holiday!
#FourthOfJuly #July4 #DrugDocs
July 4, 2026 at 3:07 PM
🎆 Happy Fourth of July!
Wishing our friends, colleagues, partners, and followers across the United States a wonderful Independence Day filled with celebration, good time with family and friends, and summer traditions.
Have a safe, happy, and memorable holiday!
#FourthOfJuly #July4 #DrugDocs
Wishing our friends, colleagues, partners, and followers across the United States a wonderful Independence Day filled with celebration, good time with family and friends, and summer traditions.
Have a safe, happy, and memorable holiday!
#FourthOfJuly #July4 #DrugDocs
📊 Clinical evidence is strongest when trial populations reflect the patients who may ultimately use a therapy.
A recent PharmaTimes article explores representation in clinical development.
📖 Read more: magazine.pharmatimes.com/collections/...
#DrugDocs #ClinicalTrials #ClinicalEvidence
A recent PharmaTimes article explores representation in clinical development.
📖 Read more: magazine.pharmatimes.com/collections/...
#DrugDocs #ClinicalTrials #ClinicalEvidence
10-12 A design for life
This month's PharmaTimes champions the human touch in healthcare, exploring diversity in clinical trials and the role of AI. Plus health comms, probiotics, medicine governance, GLP-1s, and the Clinica...
magazine.pharmatimes.com
June 29, 2026 at 3:00 PM
📊 Clinical evidence is strongest when trial populations reflect the patients who may ultimately use a therapy.
A recent PharmaTimes article explores representation in clinical development.
📖 Read more: magazine.pharmatimes.com/collections/...
#DrugDocs #ClinicalTrials #ClinicalEvidence
A recent PharmaTimes article explores representation in clinical development.
📖 Read more: magazine.pharmatimes.com/collections/...
#DrugDocs #ClinicalTrials #ClinicalEvidence
💉 Vaccine innovation in focus:
Merck's Capvaxive® gained expanded approval for certain high-risk children, while Moderna's mRNA flu vaccine received support from FDA advisers.
Read more here:
📖 www.reuters.com/business/hea...
📖 www.reuters.com/legal/litiga...
#DrugDocs #Vaccines #mRNA
Merck's Capvaxive® gained expanded approval for certain high-risk children, while Moderna's mRNA flu vaccine received support from FDA advisers.
Read more here:
📖 www.reuters.com/business/hea...
📖 www.reuters.com/legal/litiga...
#DrugDocs #Vaccines #mRNA
Merck's pneumococcal vaccine wins US approval for high-risk children, teens
Drugmaker Merck said on Thursday the U.S. health regulator has approved an expanded use of its pneumococcal vaccine for children and teenagers who face a higher risk of catching the bacterial diseas...
www.reuters.com
June 24, 2026 at 2:31 PM
💉 Vaccine innovation in focus:
Merck's Capvaxive® gained expanded approval for certain high-risk children, while Moderna's mRNA flu vaccine received support from FDA advisers.
Read more here:
📖 www.reuters.com/business/hea...
📖 www.reuters.com/legal/litiga...
#DrugDocs #Vaccines #mRNA
Merck's Capvaxive® gained expanded approval for certain high-risk children, while Moderna's mRNA flu vaccine received support from FDA advisers.
Read more here:
📖 www.reuters.com/business/hea...
📖 www.reuters.com/legal/litiga...
#DrugDocs #Vaccines #mRNA
💉📉 Retatrutide moves one step closer to approval.
New Phase 3 results showed average weight loss of 28.3% over 80 weeks, approaching bariatric surgery outcomes.
📖 Read more: www.scientificamerican.com/article/next...
#DrugDocs #GLP1 #Obesity
New Phase 3 results showed average weight loss of 28.3% over 80 weeks, approaching bariatric surgery outcomes.
📖 Read more: www.scientificamerican.com/article/next...
#DrugDocs #GLP1 #Obesity
Trial of next-gen weight-loss drug retatrutide shows users lose almost a third of their body weight
While drugs such as Wegovy target a single gut hormone, retatrutide is among a new class of GLP-1 drugs that aims at three hormone receptors
www.scientificamerican.com
June 12, 2026 at 2:38 PM
💉📉 Retatrutide moves one step closer to approval.
New Phase 3 results showed average weight loss of 28.3% over 80 weeks, approaching bariatric surgery outcomes.
📖 Read more: www.scientificamerican.com/article/next...
#DrugDocs #GLP1 #Obesity
New Phase 3 results showed average weight loss of 28.3% over 80 weeks, approaching bariatric surgery outcomes.
📖 Read more: www.scientificamerican.com/article/next...
#DrugDocs #GLP1 #Obesity
🧠📊 AI doesn't fix weak data—it amplifies it.
A new article explores why high-quality real-world evidence depends on strong data foundations, expert review, and rigorous validation.
Trustworthy evidence starts with trustworthy data.
📖 Read more below.
#DrugDocs #RWE #AI
A new article explores why high-quality real-world evidence depends on strong data foundations, expert review, and rigorous validation.
Trustworthy evidence starts with trustworthy data.
📖 Read more below.
#DrugDocs #RWE #AI
Real-World Evidence in the AI Era: What You Can Unlock Depends on What You Build On
Written by Guy Amster, Senior Principal Machine Learning Engineer, Flatiron Health | The differentiator isn't algorithms; it's data quality. Discover the two critical bottlenecks in oncology RWE and h...
www.fiercepharma.com
June 10, 2026 at 2:25 PM
📊 Top 3 searched drugs on DRUGDOCS® in May:
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Zolymbus® – Glaucoma ophthalmic gel
3️⃣ Kadcyla® – HER2-targeted antibody-drug conjugate
Explore the evidence: drugdocs.com
#DrugDocs #ClinicalEvidence #Oncology
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Zolymbus® – Glaucoma ophthalmic gel
3️⃣ Kadcyla® – HER2-targeted antibody-drug conjugate
Explore the evidence: drugdocs.com
#DrugDocs #ClinicalEvidence #Oncology
June 8, 2026 at 3:21 PM
📊 Top 3 searched drugs on DRUGDOCS® in May:
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Zolymbus® – Glaucoma ophthalmic gel
3️⃣ Kadcyla® – HER2-targeted antibody-drug conjugate
Explore the evidence: drugdocs.com
#DrugDocs #ClinicalEvidence #Oncology
1️⃣ Epidiolex® – Cannabidiol for rare epilepsy
2️⃣ Zolymbus® – Glaucoma ophthalmic gel
3️⃣ Kadcyla® – HER2-targeted antibody-drug conjugate
Explore the evidence: drugdocs.com
#DrugDocs #ClinicalEvidence #Oncology
Pride reminds us that dignity should never depend on who someone is, who they love, or how they identify.
At DRUGDOCS, we believe every person deserves to be met with respect, care, and without assumptions.
That commitment matters during Pride and every day after.
Happy Pride Month. ❤️🧡💛💚💙💜
At DRUGDOCS, we believe every person deserves to be met with respect, care, and without assumptions.
That commitment matters during Pride and every day after.
Happy Pride Month. ❤️🧡💛💚💙💜
June 1, 2026 at 6:23 PM
Pride reminds us that dignity should never depend on who someone is, who they love, or how they identify.
At DRUGDOCS, we believe every person deserves to be met with respect, care, and without assumptions.
That commitment matters during Pride and every day after.
Happy Pride Month. ❤️🧡💛💚💙💜
At DRUGDOCS, we believe every person deserves to be met with respect, care, and without assumptions.
That commitment matters during Pride and every day after.
Happy Pride Month. ❤️🧡💛💚💙💜
On this #MemorialDay, we at DRUGDOCS, take a moment to honor the brave men and women who made the ultimate sacrifice. Their courage and service will always be remembered.
May 25, 2026 at 8:55 PM
On this #MemorialDay, we at DRUGDOCS, take a moment to honor the brave men and women who made the ultimate sacrifice. Their courage and service will always be remembered.
🧠 The FDA recently announced new support for studies involving psilocybin, methylone, and noribogaine-based therapies for depression, PTSD, and alcohol use disorder.
Watching how this space evolves and whether future approvals may join the body of evidence available on DRUGDOCS.
📖 Read more below.
Watching how this space evolves and whether future approvals may join the body of evidence available on DRUGDOCS.
📖 Read more below.
FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order
On April 18, President Trump issued an Executive Order directing the U.S. Department of Health and Human Services (HHS) to accelerate access to treatments for patients with serious mental illness, inc...
www.fda.gov
May 19, 2026 at 6:56 PM
🧠 The FDA recently announced new support for studies involving psilocybin, methylone, and noribogaine-based therapies for depression, PTSD, and alcohol use disorder.
Watching how this space evolves and whether future approvals may join the body of evidence available on DRUGDOCS.
📖 Read more below.
Watching how this space evolves and whether future approvals may join the body of evidence available on DRUGDOCS.
📖 Read more below.